Moderna announces Hong Kong expansion

Its new subsidiary will provide a local presence for improved logistics.

Biotechnology company Moderna announced its plans to establish a new subsidiary in Hong Kong alongside Malaysia, Taiwan, and Singapore. With offices in Japan, South Korea, and Australia, Moderna continued its expansion to the Asia-Pacific (APAC) region.

"The year 2021 was a year of impact for Moderna, and I am proud to see continued growth in 2022 as we expand our presence in Asia. After a decade of pioneering the development of our mRNA platform, we were ready to play a critical role in combating the COVID-19 pandemic globally," said CEO Stéphane Bancel.

Moderna is actively recruiting a team to build a strong presence in the market as its mRNA therapeutics pipeline grows to benefit Hong Kong and the wider region. 

It is currently is developing mRNA medicines to potentially prevent and treat diseases with significant unmet needs across infectious diseases, immuno-oncology, rare and ultra-rare diseases, and autoimmune diseases.